219 results about "Purine derivative" patented technology

PCT No. PCT/JP97/02310 Sec. 371 Date Mar. 3, 1998 Sec. 102(e) Date Mar. 3, 1998 PCT Filed Jul. 3, 1997 PCT Pub. No. WO98/01448 PCT Pub. Date Jan. 15, 1998This invention relates to novel purine derivatives of formula (I): where R2 and R9 are hydrocarbon groups, R6 is an amino group and R8 is a hydroxyl, or acyloxy group. These purine derivatives are effective at promoting secretion of interferon in patients, and can be used to treat diseases against which interferon is effective.

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

Novel compound having the following formula:

wherein W represents a hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_3-6 cycloalkyl, or an optionally substituted C_1-6 haloalkyl, Y represents a hydrogen, or a saccharide, Q represents a quinoline or isoquinoline. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same.

The invention relates to 6-(alkylbenzylamino)purine derivatives of the general formula I for use as cytokinin receptor antagonists, wherein R1 is selected from the group comprising hydroxyl, amino, nitro, thio and alkyl group, and R2 denotes one to four alkyl groups. The invention also relates to preparations containing these derivatives.

A container comprising a polyester composition with enhanced carbon dioxide and oxygen barrier properties is provided. The polyester composition comprises a polyester and a purine derivative. In a particular embodiment, the purine derivative comprises a purine dione, such as caffeine.

A purine derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring and has two nitrogen atoms in the six-membered ring. The moiety A can be a purine moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

Compositions and methods for enhancing adhesion between a copper conducting layer and a dielectric material during manufacture of a printed circuit board. Conditioning compositions contain a functional organic compound and preferably a transition metal ion. The functional organic compound, e.g., a purine derivative, is capable of forming a self-assembled monolayer. Adhesion promoting compositions contain an acid, preferably an inorganic acid, and an oxidant. The latter compositions may also contain a corrosion inhibitor and/or a transition metal ion selected from among Zn, Ni, Co, Cu, Ag, Au, Pd or another Pt group metal. The corrosion inhibitor may comprise a nitrogen-containing aromatic heterocyclic compound.

Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A₃ adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R₁-R₆ are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A₃ versus the A₁ receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.

A multilayer container having enhanced gas barrier properties comprises at least two outer layers comprising a polymer matrix, and at least one barrier layer disposed between the at least two outer layers. The at least one barrier layer comprises a first polymer composition comprising a polymer matrix and a low molecular weight additive. In a particular embodiment, the low molecular weight additive comprises a purine derivative, such as caffeine, and is present in the multilayer container in an amount in the range of about 0.2 to about 10 weight percent of the container.

This application relates to a purine derivative and pharmaceutical compositions which are useful for treating a hepatitis B viral infection or a hepatitis C viral infection.

The present invention relates to compounds of formula (I):

wherein;

• • R¹ represents hydrogen or C_1-3alkyl;
  • n is an integer having a value of 1 to 5;
  • X represents O or NH;
  • Y represents C or N;

or a pharmaceutically acceptable salt thereof, have been shown to be inducers of human interferon and may possess an improved profile with respect to known inducers of human interferon, for example enhanced potency. The compounds of the invention may therefore be useful in the treatment of various disorders, in particular the treatment of infectious diseases, cancer, allergic diseases and other inflammatory conditions, and their use as vaccine adjuvants.

The present invention relates to compounds of formula 1

or pharmaceutically acceptable salts thereof, wherein

• one of R¹ and R² is methyl, ethyl or isopropyl, and the other is H;
• R³ and R⁴ are each independently H, branched or unbranched C₁-C₆ alkyl, or aryl, and wherein at least one of R³ and R⁴ is other than H;
• R⁵ is a branched or unbranched C₁-C₅ alkyl group or a C₁-C₆ cycloalkyl group, each of which may be optionally substituted with one or more OH groups;
• R⁶, R⁷, R⁸ and R⁹ are each independently H, halogen, NO₂, OH, OMe, CN, NH₂, COOH, CONH₂, or SO₂NH₂. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

The present invention relates to compounds of formula (I)

or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R¹, R², R³, R⁴, R⁵, R^5a, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

The invention provides a method for preparing an intermediate of trajenta and belongs to the technical field of pharmacy. The method comprises the following steps: reacting 8-bromo-7-(2-butynyl)-3-methyl-1-purine-2,6-dione with 2-chloromethyl-4-methylquinazoline to obtain a reaction liquid; reacting the reaction liquid with (R)-3-tert-butyloxycarboryl-aminopiperidine to obtain 8-[(3R)-3-(tert-butyloxycarboryl-amino)-1-piperidyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)-methyl]-1H-purine-2,6-dione. In the reacting process, an intermediate product is not separated. According to the preparation method, the intermediate product does not need to be separated or purified, the operation is simplified, the yield is high, the production cost is reduced, and the industrial production is benefited.